Division of Nephrology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.
PLoS One. 2023 Sep 14;18(9):e0291266. doi: 10.1371/journal.pone.0291266. eCollection 2023.
COVID-19 carries a high risk of morbidity and mortality in dialysis patients. Multiple SARS-CoV-2 variants have been identified since the start of the COVID-19 pandemic. The current study aimed to compare the incidence and outcomes of the COVID-19 Omicron dominant period versus other pre-Omicron period in hemodialysis patients. In this observational, analytical, retrospective, nationwide study, we reviewed adult chronic hemodialysis patients between March 1, 2020, and January 31, 2022. Four hundred twenty-one patients had COVID-19 during the study period. The incidence of COVID-19 due to the Omicron dominant period was significantly higher than other pre-Omicron period (30.3% vs. 18.7%, P<0.001). In contrast, the admission rate to ICU was significantly lower in the Omicron dominant period than in the pre-Omicron period (2.8% vs. 25%, P<0001) but with no significant difference in ICU length of stay. The mortality rate was lower in the Omicron dominant period compared to the pre-Omicron period (2.4% vs. 15.5%, P<0.001). Using multivariate analysis, older age [OR 1.093 (95% CI 1.044-1.145); P<0.0001] and need for mechanical ventilation [OR 70.4 (95% CI 20.39-243.1); P<0.0001] were identified as two independent risk factors for death in hemodialysis patients with COVID-19. In Conclusion, the COVID-19 Omicron variant had a higher incidence and lower morbidity and mortality than pre-Omicron period in our hemodialysis population.
新冠病毒在透析患者中具有较高的发病率和死亡率。自新冠疫情开始以来,已经发现了多种 SARS-CoV-2 变体。本研究旨在比较奥密克戎主导期与透析患者奥密克戎前时期的新冠发病率和结局。在这项观察性、分析性、回顾性、全国性研究中,我们回顾了 2020 年 3 月 1 日至 2022 年 1 月 31 日期间的成年慢性血液透析患者。在研究期间,有 421 名患者发生了 COVID-19。奥密克戎主导期的 COVID-19 发病率明显高于奥密克戎前时期(30.3%比 18.7%,P<0.001)。相比之下,奥密克戎主导期的 ICU 入住率明显低于奥密克戎前时期(2.8%比 25%,P<0001),但 ICU 住院时间无显著差异。奥密克戎主导期的死亡率明显低于奥密克戎前时期(2.4%比 15.5%,P<0.001)。使用多变量分析,年龄较大[比值比 1.093(95%置信区间 1.044-1.145);P<0.0001]和需要机械通气[比值比 70.4(95%置信区间 20.39-243.1);P<0.0001]被确定为透析患者 COVID-19 死亡的两个独立危险因素。总之,在我们的血液透析人群中,奥密克戎变异株的 COVID-19 发病率较高,发病率和死亡率较低。
MMWR Morb Mortal Wkly Rep. 2022-2-11
BMJ Glob Health. 2023-5
Nephrology (Carlton). 2022-8